Functional deficiency of NBN, the Nijmegen breakage syndrome protein, in a p.R215W mutant breast cancer cell line

Bianca Schröder-Heurich, Natalia Bogdanova, Britta Wieland, Xiaoxi Xie, Monika Noskowicz, Tjoung-Won Park-Simon, Peter Hillemanns, Hans Christiansen and Thilo Dörk

Abstract

Background: Mutations in NBN, the gene for Nijmegen Breakage Syndrome (NBS), are thought to predispose women to developing breast cancer, but a breast cancer cell line containing mutations in NBN has not yet been described. The p.R215W missense mutation occurs at sub-polymorphic frequencies in several populations. We aimed to investigate its functional impact in breast cancer cells from a carrier of this NBN mutation.

Methods: Breast cancer cell lines were screened by immunoblotting for NBN protein levels, and the NBN coding region was sequenced for mutation analysis. Radiosensitivity assays and functional studies were performed through immunocytochemistry and immunoblotting, and flow cytometry was employed to assess cell cycle progression. Impedance measurements were used to study the consequences of PARP1 inhibition. Statistical comparisons between cell lines were performed using t-tests.

Results: HCC1395 breast cancer cells exhibited reduced NBN protein levels. Direct sequencing identified the NBN p. R215W mutation in the hemizygous state, in addition to a truncation in BRCA1. Mutations in both genes were already present in the heterozygous state in the patient’s germline. HCC1395 cells were highly radiosensitive, susceptible to apoptosis and were deficient in the formation of NBN foci. There was also evidence for some impairment in the formation of γH2AX, MDC1, and 53BP1 foci after irradiation; these foci appeared smaller and irregular compared with repair foci in wild-type cells, although ATM signalling was largely unaffected. In line with their deficiency in NBN and BRCA1, HCC1395 cells were particularly sensitive to PARP1 inhibition.

Conclusion: Our results indicate that the p.R215W mutation in the HCC1395 breast cancer cell line impairs NBN function, making this cell line a potentially useful cellular model for studying defective NBN protein within a mutant BRCA1 background.

Keywords: Breast carcinoma, DNA damage repair, DNA double strand break repair disorder, Ionising radiation sensitivity, MRN complex

Background

Breast cancer is a genetically heterogeneous disease, and several predisposing genes are involved in DNA double strand break repair [1-3]. One of these is NBN, the gene for Nijmegen Breakage Syndrome (NBS) [4-6]. NBS is an autosomal recessive chromosomal instability disorder characterised by microcephaly, stunted growth, immunodeficiency, a high cancer predisposition and a marked sensitivity towards ionising radiation [7]. The syndrome is most common in Eastern Europe due to a Slavic founder mutation, c.657del5, in the NBN gene [4]. This gene encodes a 754 amino-acid protein named NBN, p95 or nibrin, that interacts with the MRE11 and RAD50 proteins in sensing DNA damage and aids to recruit the ataxia-telangiectasia mutated kinase, ATM, to the sites of DNA double-strand breaks [5,8]. It further interacts at the DNA damage sites with phosphorylated histone H2AX (γH2AX) through its tandem breast cancer carboxy-
terminal (BRCT) domain [9,10]. Loss of NBN function leads to radiosensitive DNA synthesis and deficiencies in proper DNA double-strand break repair [11,12].

While biallelic mutations in the NBN gene give rise to NBS, monoallelic mutations have been found to predispose the heterozygous carriers within NBS families towards malignancies [13]. Furthermore, an increased frequency of the most common NBN mutation c.657del5 has been observed in Eastern European breast cancer patients compared with healthy controls [14–19]. A missense mutation, p.R215W, in the tandem BRCT domain has been suggested as a more wide-spread candidate breast cancer susceptibility allele [15,19]. Compound heterozygosity of the p.R215W substitution with the c.657del5 mutation has been reported in NBS patients with severe disease [20]. In vitro mutagenesis studies indicated that p.R215W might be a functional mutation that impairs the association of NBN with γH2AX [21]. However, further cellular models for this missense mutation would be useful to fully clarify its role in breast cancer.

In the present study we report on the identification of a breast cancer cell line, HCC1395, that harbors p.R215W in the hemizygous state, and we investigate the functional competence of the mutant NBN protein in this cell line.

Methods
Cell culture
Cell lines were obtained from the American Type Culture Collection (ATCC) in 2010. Human breast cancer epithelial cell lines HCC1395 and HCC1937 were cultured in RPMI 1640 with 10% fetal calf serum, 500 U/ml penicillin, 0.5 mg/ml streptomycin and 2 mM L-Glutamine. Lymphoblastoid cells HCC1395 BL were cultured in RPMI 1640 with 15% fetal calf serum and supplements as above. Human normal breast epithelial MCF10A cells were cultured in MEBM, supplemented with MEGM Single Quots according to the manufactures instruction (Lonza). All cells were grown at 37°C in a humidified atmosphere supplemented with 5% CO₂. Ionizing radiation (IR) with doses between 0.1 – 6 Gy was applied to the cells using a Mevatron MD-2 accelerator (Siemens, Munich, Germany). Olaparib was purchased from LC Laboratories (Woburn, MA, USA), dissolved in DMSO and stored at −20°C before usage.

Genetic analysis
Genomic DNA was extracted from the cultured breast cancer epithelial cells using proteinase K digestion and phenol-chloroform extraction. The coding region of NBN and selected regions of BRCA1 (exon 20), BRCA2 (exon 11) and TP53 (exon 5) gene were amplified by PCR using the primer pairs given in Additional file 1: Table S1, and purified PCR products were subjected to direct sequencing using BigDye v1.1 terminator chemistry and a 3100 Avant capillary sequencer (Life Technologies). Sequencing data were analyzed with the Sequencing Analysis 5.1.1 software.

Colonies formation assay
Cells were seeded in six-well plates and, after 24 hours incubation, were irradiated with doses between 0–6 Gy. Radiation doses between 0.1-1 Gy or between 2–6 Gy were applied in different experiments. Plating efficiency was consistently lower for HCC1395 cells than for MCF10A cells (about 58% for MCF10A compared with about 2% in HCC1395). Medium was gently changed every two days. After 5–7 days incubation for MCF10A and 10–12 days incubation for HCC1395, colonies were fixed with 3% (w/v) PFA, 2% (w/v) sucrose in PBS for 10 min, stained with 0.5% (w/v) crystal violet and counted by microscopy. Surviving colonies were counted as positive above a threshold of 50 cells. The survival fraction (SF) of irradiated cells was expressed as a percentage of colonies per seeded cells after normalisation by the plating efficiency of unirradiated cells. Each experiment was performed at least 3 times with both cell lines.

Lysate preparation and immunoblotting
For preparation of protein extracts, cells were lysed in cell extraction buffer (50 mM Tris pH 7.4, 150 mM NaCl, 2 mM EGTA, 2 mM EDTA, 25 mM NaF, 0.1 mM Na₃VO₄, 0.1 mM PMSE, 2 mg/ml Leupeptin, 2 mg/ml Aprotinin, 0.2% Triton X-100, 0.3% NonidetP-40) for 30 min on ice. Protein extracts were cleared through centrifugation at 16100 rcf for 15 min, and supernatants were separated through SDS-PAGE and transferred to nitrocellulose membranes. Antibodies to NBN, SMC1-pS966, KAP1-pS824 were obtained from Novus Biologicals (rabbit polyclonal); anti CHEK2-pS19 from Cell Signaling (rabbit polyclonal); anti RAD50 (mouse monoclonal) from Abcam; anti MRE11 (mouse monoclonal 12D7) from GeneTex; PARP1 and cleaved PARP1 (rabbit polyclonal) from Cell Signaling, and anti β-Actin (mouse monoclonal) from Sigma. Anti-mouse and anti-rabbit horseradish peroxidases labelled secondary antibodies were purchased from GE Healthcare. Visualization of immunoactive bands was performed by using ECL (Thermo Scientific/Pierce), and their intensity was determined using ImageJ quantitation software.

Immunocytochemistry
Cells grown on cover glasses in six-well plates were fixed with 3% (w/v) PFA, 2% (w/v) Sucrose in PBS for 10 min. Cells were permeablized with 0.2% (v/v) Triton X-100 in PBS. Antibodies against NBS1 (Novus Biologicals), MDC1 (Abcam), Histone H2A.x Phospho (S139) (Millipore) and
53BP1 (Bethyl Laboratories) were incubated in 2% (w/v) normal goat serum (Dianova) for 2 hrs. After PBS washing, cells were incubated with FITC-conjugated anti-mouse IgG antibody (Dianova), Alexa Fluor anti-mouse IgG 488 or Alexa Fluor anti-rabbit IgG 546 (Invitrogen) for 1.5 hrs. DNA was counterstained with DAPI (Invitrogen) and cells were mounted with Pro-Long® Gold (Invitrogen). Foci were counted under a Leica DMi6000B microscope, and results from four independent experiments were statistically analysed using GraphPad Prism 4 with a t-test. P values below $\alpha < 0.05$ were considered significant. For a more detailed inspection of the size and area of foci, images were taken as z-stacks by using a Leica TCS SP2 confocal microscope (40× or 63× magnification) and image acquisition was carried out using CorelPhotoPaintX4 Software and evaluated using Imagej software. The number of pixels was determined as a proxy for the foci area.

Flow cytometry
For DNA content analysis cells were irradiated with 6 Gy, were fixed in 70% ethanol after the indicated time-points (24, 48, 72, 96 hours) and were stained with propidium iodide over night at 4°C. Data acquisition and analysis were performed with a FACS Calibur (BD) flow cytometer and Summit V5.1 software (Beckman Coulter). Results from three independent experiments were analysed using GraphPad Prism 4.

Impedance measurements
For impedance measurements we used the xCELligence System (Roche) that provides a highly sensitive method to measure the cell index as a proxy of cell adhesion, proliferation, cell death and morphological alterations. Cell lines were subconfluent, and each cell line has been optimized in previous titration experiments so that cell type-specific optimal conditions for the seeding rate and confluence were obtained for the real-time measurement in these experiments. Cells were seeded at 5000 cells per well in quadruplicates in E-Plate VIEW 96 (Roche) and left untreated for 24 hrs within the RTCA SP station positioned in a 37°C incubator with 5% CO2 supply. For monitoring compound mediated cytotoxicity, cells were then treated with DMSO only or with 0.2 µM, 1 µM or 5 µM olaparib and incubated for an additional 72 hrs. The Cell Index was plotted and analysed using RTCA software 1.2.1 (Roche).

Results
We screened by immunoblotting six breast cancer cell lines that are frequently used in molecular cancer research (HCC38, HCC1395, HCC1599, HCC1806, HCC1937, MDA-MB231), for possible deficiencies in the proteins of the MRE11-RAD50-NBN (MRN) complex. One cell line, HCC1395, exhibited significantly reduced levels in NBN that were not seen in the wildtype breast epithelial cell line MCF10A or in the other tested breast cancer lines (Figure 1A). NBN was observed only at 30-40% of wildtype levels in HCC1395 cells, but the protein appeared to be phosphorylated correctly following damage as noted by an electrophoretic mobility shift after irradiation with 6 Gy (Figure 1A).

To identify the molecular basis for the reduced NBN level, the whole NBN coding region was sequenced and the missense mutation p.R215W was uncovered in the hemizygous state (Figure 1B). This result was unexpected since previous genome-wide sequencing studies had not found a NBN mutation in HCC1395 cells [22-24]. We therefore investigated lymphoblastoid cells from the same breast cancer patient of whom the HCC1395 cell line had been established. Direct sequencing revealed the p.R215W mutation in the heterozygous state in the lymphoblastoid cells (Figure 1B) indicating that it is a germline mutation and has undergone loss of heterozygosity in the breast tumour cells. The same was confirmed for a mutation in BRCA1, p.R1751X, that also was heterozygous in the lymphoblastoid cells and hemizygous in the HCC1395 cell line [24] (Additional file 2: Figure S1). BRCA1 interacts with the MRN complex, however, BRCA1 deficiency could not account for the reduced levels of NBN, since the BRCA1 mutant HCC1937 cell line has normal levels of NBN (Figure 1A).

Because NBN deficient cells from NBS patients are highly radioresistant, we tested whether the p.R215W missense mutation was also associated with an increased sensitivity towards ionising radiation in HCC1395 cells. As shown in Figure 2A and Additional file 3: Figure S2, the HCC1395 cell line was highly radiosensitive in a colony formation assay and could be distinguished from the wildtype response in MCF10A cells even at moderate doses of radiation down to 100 mGy (Figure 2A). This cellular radiosensitivity could not be associated with overt cell cycle abnormalities, such as early G2 accumulation, as judged by flow cytometric analysis of HCC1395 cells 24–72 hrs after irradiation (Additional file 4: Figure S3). However, increased susceptibility to apoptosis was indicated by a markedly increased level of PARP1 cleavage in immunoblots from irradiated HCC1395 cells. PARP1 expression was elevated in HCC1395 cells, and the ratio of cleaved PARP1 versus total PARP1 was about 10% in unirradiated and 30% in irradiated HCC1395 cells whereas cleaved PARP was poorly detectable in MCF10A cells (Figure 2B).

Because the cellular radiation response is mediated through a cooperation of NBN with ATM, we investigated the radiation-induced kinase activity of ATM in HCC1395 cells. There was little difference between the NBN mutant cells and MCF10A in the radiation-induced phosphorylation of SMC1, CHEK2 or KAP1,
respectively (Figure 2C). This was independent of total protein levels as exemplified for KAP1 in Additional file 5: Figure S4. While HCC1395 cells showed a somewhat higher basic level of phosphorylation in the unirradiated state, the fact that irradiated cells reached the same level of phosphorylation as wildtype cells indicated a largely unaffected ATM kinase activity towards these major substrates within the dose range studied (0.5 – 6 Gy; Figure 2C).

In order to investigate the molecular basis of radiation sensitivity in HCC1395 cells in more detail, we analysed radiation induced foci by immunocytochemical analyses of three repair proteins γH2AX, 53BP1 and MDC1. In HCC1395 cells, foci for these three proteins were generally less intense and appeared smaller than in MCF10A cells. In a quantitative approach of counting foci with conventional fluorescence microscopy on MCF10A, HCC1395 and HCC1937 under the same conditions, the percentages...
of γH2AX and MDC1 foci were significantly reduced in HCC1395 cells compared to wildtype MCF10A at 30 min after irradiation with either 1.5 or 6 Gy, whereas they were at least as high as wildtype in HCC1937 cells in which they also persisted at 24 hours after irradiation (Figure 3A).

A closer inspection using confocal laser microscopy revealed a smaller and a more fuzzy appearance of foci in HCC1395 cells compared with MCF10A. A significant reduction in the size of γH2AX foci was noted as determined by measuring the γH2AX foci area in HCC1395 (Figures 3B–E). When staining against NBN itself, wildtype MCF10A cells showed multiple discrete NBN foci after irradiation whereas no such NBN foci were detected in HCC1395 cells, indicating a strongly reduced capability of p.R215W NBN to accumulate in radiation-induced foci (Figure 4).

Because NBN may facilitate homologous recombinational repair [25,26], and PARP1 activity has been reported to be aberrantly high in NBS cells [27], we speculated that PARP1 inhibition may be effective in HCC1395 cells. We therefore treated HCC1395 cells with different doses of olaparib, a known PARP1 inhibitor used in clinical trials, and determined its effect on cellular viability and proliferation using real time monitoring of cellular impedance.

Olaparib significantly decreased the cell index at doses as low as 0.2 μM. At this concentration, no such effect of olaparib was observed in MCF10A (Additional file 6: Figure S5), nor in HCC1937, suggesting a particular sensitivity of HCC1395 cells with their combined mutations in BRCA1 and NBN towards PARP1 inhibition.

Discussion
In a search for breast cancer cell lines with deficiencies in the MRN-ATM pathway, and thus defective DNA double strand break response, we here describe the triple-negative breast cancer cell line, HCC1395, as being mutated in the NBN gene. HCC1395 is a known breast cancer cell line and has been included in previous genome-wide sequencing studies [22-24] but the NBN mutation p.R215W had not been uncovered. At the time of submission, database mining of available cancer cell lines in the COSMIC database (http://cancer.sanger.ac.uk/cosmic/) failed to identify any other line with the p.R215W NBN mutation, and also did not reveal any other breast cancer cell line with a coding NBN mutation, so that HCC1395 may provide a unique source for studying the molecular consequences of NBN deficiency. The observation that p.R215W had already been present as a germ-line mutation in the heterozygous patient and underwent loss of heterozygosity in the tumour would be in line with the view that it represents a driver rather than a passenger mutation during tumorigenesis, and is consistent with the previously reported loss of heterozygosity in breast carcinomas harboring the NBN*657del5 mutation [14].

One consequence of the p.R215W mutation appears to be a somewhat reduced stability of the NBN protein.
Figure 3 (See legend on next page.)
which was expressed at a lower level than would be expected for a hemizygous situation. This did not affect the levels of MRE11A or RAD50, consistent with the report that BRCT mutations in NBN do not interfere with MRN complex formation in vitro [28]. The reduced level of p.R215W mutant protein is also consistent with previous results from lymphoblastoid cells of p.R215W/c.657del5 compound heterozygous NBS patients which similarly showed markedly reduced nibrin levels [19,20]. Nevertheless, the residual NBN protein was easily detectable and, at the reduced level, appeared to undergo a rapid mobility shift after irradiation as expected for normally activated NBN. An unimpaired phosphorylation shift of NBN after irradiation has similarly been found in the compound heterozygous NBS patient cells [20] and may indicate that the p.R215W substitution does not strongly disturb the ATM-mediated phosphorylation of NBN at the more distant serine-278 and serine-343 sites. Furthermore, although NBN has been shown to be required for full ATM activation after irradiation [11,29] and particularly for its phosphorylation of SMC1 [30,31] the p.R215W mutant did not seem to strongly disturb the ATM-mediated phosphorylation of three different substrates including SMC1 after irradiation in HCC1395 cells, suggesting that it still functions in the intra-S-phase checkpoint. This appears to be inconsistent with a recent study that reports impairment of ATM-mediated phosphorylation through p.R215W in retrovirally transduced fibroblasts [32] but is in agreement with the normal behaviour of other BRCT mutants [28] and is supported by the flow cytometric analyses of HCC1395 cells which did not uncover marked cell cycle abnormalities, such as a rapid G2 accumulation due to radioresistant DNA synthesis, after up to 72 hours. In line with this, previous work had indicated that the BRCT domain of NBN is not required for inhibition of DNA synthesis [11] or for cell cycle checkpoint regulation which rather may be mediated by the FHA domain that is preserved in the p.R215W mutant [33]. The retained activation of the cohesion protein, SMC1, may help to suppress chromatid-type aberrations [34], and such aberrations are indeed lacking in p.R215W/c.657del5 compound heterozygous NBS patients [20].

The BRCT domain, initially described in BRCA1, is a phosphoprotein binding module that is common in several DNA damage responsive proteins [35,36] and, in case of NBN, has been implicated in the binding of phosphorylated H2AX [9]. Phosphorylation of H2AX at Ser139 is among the first events of the repair of double strand breaks [37]. The gross accumulation of γH2AX into foci, like those of MDC1 and 53BP1, appeared to be complete in HCC1395 cells although smaller foci could well be detected. It is possible that, after an initial phosphorylation of these repair proteins, p.R215W mutant NBN fails to properly localize to γH2AX and to recruit or stabilize ATM which may be required for a second wave of phosphorylation and focus extension. Our results support a previous study, using a targeted mutagenesis approach [21], which showed that mutation R215W prevented the binding of NBN to γH2AX following radiation, and suggests a functional relevance for this mutation in protein-protein interactions. This view is further supported by molecular modelling of the tandem BRCT domain of NBN in which the R215 residue, similar to the R1989 residue in MDC1, appears to direct the relative orientation of both BRCT domains and thereby regulate γH2AX recognition [21]. In a study of additional single mutations of either the FHA or BRCT
domains, only a small fraction of mutant NBN accumulated along DNA damage tracks labelled by γH2AX after irradiation [33], and given that only one BRCT domain had been mutated, it seems plausible that p.R215W may have a stronger effect than the p.K160R mutant used in that study.

The results obtained in HCC1395 might have more general implications for breast cancer as they strongly indicate functional and clinical relevance for a missense mutation that is not uncommon among Europeans. p.R215W has not been studied in the homozygous state, thus far, because no homozygous individual has been identified despite the modestly high prevalence of around 1/200 in some populations [19,20]. As suggested by Seemannova and co-workers, homozygosity for the p.R215W mutation may lead to early embryonic lethality, albeit the data here clearly indicate that some residual expression and function is associated with this mutation. Of note, it appears from Figure 2C as well as based on Figure 2B that the hemizygous HCC1395 line may be suffering considerable damage even without additional endogenous exposure (higher levels of pSMC1, and Chk2 phosphorylation and PARP cleavage in 0 Gy irradiated samples) and this finding may be related to its poor growth overall. These features are also commonly observed for classical NBN mutant lines. Heterozygosity for p.R215W, as observed for the patient BL1395, has been previously associated with breast cancer in some, though not all, study populations [15,19,38], and it is possible that p.R215W plays a predisposing role also for other malignancies [39]. At present, the functional impact of the p.R215W NBN defect in breast cancer susceptibility is still controversial, but evidence is accumulating that this mutation might predispose individuals to disease.

It is also possible that p.R215W exerts such a predisposing role as a modifier of penetrance for additional mutations such as in BRCA1. In fact, the HCC1395 cell line was also found to harbor a truncating BRCA1 mutation. This mutation, however, is unlikely to explain the reduced NBN levels or impaired formation of repair foci considering that BRCA1 is not upstream of NBN and was also mutated in the HCC1937 cell line which was normal in NBN and proficient in the formation of repair foci. Although we cannot formally exclude the possibility that a BRCA1 mutation augments the effect of NBN p.R215W on NBN levels and radiation-induced foci formation, the functional BRCA1 deficiency does not cause these effects as is also evidenced by the observations of normal NBN levels and foci formation in other cell lines such as HCC38 or HCC1806 which are functionally deficient in BRCA1 [40,41]. However, the presence of a BRCA1 or BRCA2 mutation has been shown to affect sensitivity towards ionising radiation [42] as well as towards PARP1 inhibition [43,44], so that these endpoints were not specific for the NBN*R215W mutant. Increased sensitivity to PARP1 inhibition has previously been reported for NBN deficient cells, and mutations in other proteins that affect HR, besides BRCA1/2, may also show some PARP1 inhibitor sensitivity [45,46]. On the other hand, increased sensitivity to PARP1 inhibition is a known feature of BRCA1 and BRCA2 mutant cells, and since we found HCC1395 cells to harbour a BRCA1 truncation in the hemizygous and a BRCA2 mutation in the heterozygous state, it is likely that the high olaparib sensitivity is a combinatorial result and we could not fully determine in the present study to what extent these observations were due to functional deficiency in NBN, BRCA1, BRCA2 or perhaps other deficiencies. These results emphasize the need to fully explore the mutational genotypes of cell lines as well as of primary tumours before final conclusions can be drawn. The slow proliferation of HCC1395 cells and their higher genomic instability and higher apoptotic activity under basal conditions as indicated in Figures 2B, C and Additional file 6: Figure S5 may further impact on these endpoints and, given the heterogeneous background of breast tumours, additional studies of p.R215W carriers will be needed to fully elucidate this aspect and clarify whether they could perhaps benefit from treatment with PARP1 inhibitors.

Conclusion
We report for the first time the identification and characterization of a breast cancer cell line containing a NBN mutation that affects its function, providing a potentially useful cellular model for studying defective NBN protein within a mutant BRCA1 background. The data indicate that NBN*p.R215W is an unstable protein that fails to be recruited into foci after irradiation and also impairs the propagation of γH2AX repair foci. Our results furnish evidence for the functional impact of the p.R215W substitution, a suspected cancer susceptibility allele in Europeans.

Additional files

Additional file 1: Table S1. Primer pairs used for amplification and sequencing the coding region of NBN and selected regions of BRCA1 (exon 20), BRCA2 (exon 11) and TP53 (exon 5).

Additional file 2: Figure S1. Validation by direct sequencing of additional mutations in BRCA1, BRCA2 and TP53 in HCC1395 breast cancer cells. Direct sequencing of selected regions of BRCA1, BRCA2 and TP53 in HCC1395 BL lymphoblastoid cells (top) and HCC1395 breast cancer cells (bottom) to validate reported mutations and confirm the identity of HCC1395 cells. Mutated positions in BRCA1 (left panel), BRCA2 (middle panel) and TP53 (right panel) are indicated by an arrow and the mutated codon is boxed. Like the NBN mutation p.R215W, the BRCA1 mutation p. Y175X appears heterozygous in HCC1395 BL lymphoblasts but homoallelic in HCC1395 breast cancer cells, whereas TP53 and BRCA2 mutations were somatic events (with BRCA2 mutated only in the heterozygous state) in HCC1395 breast cancer cells.
Additional file 3: Figure S2. Assessment of cellular radiosensitivity in the colony formation assay (higher dose experiments). Cellular radiosensitivity of pR215W mutant cells (HCC1395) compared with wild type breast epithelial cells (MCF10A) as measured by the colony formation assay after irradiation at doses of 2, 4, or 6 Gy. The surviving fraction is presented as the mean value with SEM from at least 3 independent experiments.

Additional file 4: Figure S3. Cell cycle analysis by flow cytometry in HCC1395 breast cancer cells. Flow cytometric analyses of Sr, G1 and G2 cell population in wildtype cells (MCF10A) (A), HCC1395 (B) and HCC1937 (C) after irradiation with 6 Gy and different time points (24 hrs, 48 hrs, 72 hrs, 96 hrs). Data represented as Mean & SEM. Data for 24 hrs, 48 hrs and 72 hrs: n = 3; data for 96 hrs: n = 1.

Additional file 5: Figure S4. Immunoblot analysis of total and phosphorylated KAP1 in MCF10A and HCC1395 cells treated with different doses of irradiation. Immunoblot analysis of radiation-induced ATM signalling in HCC1395 cells compared with MCF10A. Cells were untreated or irradiated with 0.5, 1, 2, 4 or 6 Gy as indicated. Protein extracts were prepared and were analysed through Western blotting for their immuno-reactivity towards the phosphorylated form of KAP1 (pS84, upper panel) and total KAP1 (bottom panel), respectively. β-actin served as the loading control.

Additional file 6: Figure S5. Response to PARP1 inhibition in X-Celligence impedance measurements. X-Celligence impedance measurements of the pR215W mutant cell line (HCC1395) were performed over three days after addition of the PARP1 inhibitor olaparib at different concentrations (0.2 μM, 1 μM, 5 μM; increasing concentrations from top to bottom) and compared with the DMSO only control. Top: HCC1395 NBN pR215W mutant cell line; bottom: MCF10A cell line for comparison. Data are presented as mean values & SEM from quadruplicates.

Abbreviations
NBS: Nijmegen breakage syndrome; MRN: MRE11-RAD50-NBN; BRCT: Breast-cancer carboxy-terminal domain; DMSO: Dimethylsulfoxide; PFA: Paraformaldehyde; PBS: Phosphate-buffered saline; EDTA: Ethylenediamine tetraacetic acid; PMSF: Phenylmethanesulfonylfluoride.

Competing interests
All authors declare to have no financial or non-financial competing interests.

Authors’ contributions
BSH, NB and TD participated in the conception and design of the study. Data acquisition and analyses were performed by BSH, NB, XX, MN and BW. Data acquisition was supported by PH, TWPS and HC. The manuscript was drafted by BSH, NB, MN, XX, BW and TD. All authors read and approved the final manuscript.

Acknowledgments
We cordially thank Julia Menzel, Martin Werner, Jörg Frühauf and Johann Hinrich Karstens for their support at the Department of Radiation Oncology and Matthias Ballmeier for his help in flow cytometry. We are indebted to Hinrich Karstens for their support at the Department of Radiation Oncology.

References
1. Turnbull C, Rahman N: Genetic predisposition to breast cancer: past, present, and future. Annu Rev Genomics Hum Genet 2008, 9:221–345.
2. Ghousaini M, Pharoah PD, Easton DF: Inherited genetic susceptibility to breast cancer: the beginning of the end or the end of the beginning? Am J Pathol 2013, 183:1038–1051.
3. Bogdanova N, Helbig S, Dörk T: Hereditary breast cancer: ever more pieces to the polygenic puzzle. Hered Cancer Clin Pract 2013, 11:12.
4. Varon R, Vöring L, Platter M, Cersosimo KM, Chzarowska KH, Saar K, Beckmann G, Seemanová E, Cooper PR, Nowak NJ, Stumm M, Weemaes CM, Gari RA, Wilson RK, Digweed M, Rosenthal A, Sperling K, Concan P, Reis A: Nibrin, a novel DNA double-strand break repair protein, is mutated in Nijmegen breakage syndrome. Cell 1998, 93:467–476.
5. Carney JP, Rainer RS, Olivares H, Davis EM, Le Beau M, Yates JR 3rd, Hays L, Morgan WF, Petrini JH. The MRE11/Rad50 protein complex and Nijmegen breakage syndrome: linkage of double-strand break repair to the cellular DNA damage response. Cell 1998, 93:477–486.
6. Matsuura S, Tauchi H, Nakamura A, Kondo N, Sakamoto S, Endo S, Sweeets D, Solder B, Belohradsky BH, Der Kaloustian VM, Oshimura M, Iommura M, Nakamura Y, Komatsu K: Positional cloning of the gene for Nijmegen breakage syndrome. Nat Genet 1998, 19:79–181.
7. Digweed M, Sperling K: Nijmegen breakage syndrome: clinical manifestation of defective response to DNA double-strand breaks. DNA Repair 2004, 3:1207–1217.
8. Falck J, Coates J, Jackson SP: Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage. Nature 2005, 434:605–611.
9. Kobayashi J, Kobayashi J, Tauchi H, Sakamoto S, Nakamura A, Morishima K, Matsuura S, Kobayashi T, Tamaki K, Tanimoto K, Komatsu K: NBS1 localizes to gamma-H2AX foci through interaction with the FHA/BRCT domain. Curr Biol 2002, 12:1846–1851.
10. Becker E, Meyer V, Madouhal O, Guercio R: Detection of a tandem BRCT in Nbs1 and Xrs2 with functional implications in the DNA damage response. Bioinformatics 2006, 22:1289–1292.
11. Lee JH, Xu B, Lee CH, Ahn JY, Song MS, Lee H, Caman CE, Lee JS, Kastan MB, Lim DS: Distinct functions of Nijmegen breakage syndrome in ataxia telangiectasia mutated-dependent responses to DNA damage. Mol Cancer Res 2003, 1:574–681.
12. Stracker TH, Petrini JH: The MRE11 complex: starting from the ends. Nat Rev Mol Cell Biol 2011, 12:90–103.
13. Seemanová E, Jarolím P, Seeman P, Varon R, Hadac J, Butova O, Matusova H, Komatsu K: Nijmegen breakage syndrome: any role of the BRCT domain in wildtype NBS1? Biochim Biophys Acta 2009, 1793:1875–1880.
14. Górski B, Debniak T, Másocz B, Mierzejewski M, Medrek K, Cybulski C, Jakubowski A, Kurzawski G, Chosia M, Scott R, Lubinski J: Germline 657del5 mutation in the NBS1 gene in breast cancer patients. Int J Cancer 2003, 106:379–381.
15. Steffen J, Varon R, Mosor M, Maneva G, Maurer M, Stumm M, Nowakowska D, Rubach M, Kosakowska E, Ruka W, Nowacki Z, Rutkowski P, Demkow T, Sadowska M, Bzdziek M, Gawrychowski K, Sperling K: Increased cancer risk of heterozygotes with NBS1 founder mutation. J Nutr Cancer 2007, 59:1875–1880.
16. Buslov KG, Iyevleva AG, Chekmariova EV, Suspitsin EN, Togo AV, Chagunava OL, Bit-Sava EM, Semiglazov VF, Devi P, Corsetti G, Carmel H, Rusanova EV, Iryanov EN: NBS1 657del5 mutation may contribute only to a limited fraction of breast cancer cases in Russia. Int J Cancer 2005, 114:586–589.
17. Górski B, Cybulski C, Huzarski T, ByrskiT, Gronwald J, Jakubowska A, Stawicka M, Sankowski P, Wolczański M, 20. Seemanova E, Seemanova E, Sperling K, Neitzel H, Varon R, Hadac J, Butova O, Sperling K, Concan P: Exon 20 deletion in NBS1 – a founder mutation in Polish breast cancer families. Int J Cancer 2006, 111:57–61.
18. Bogdanova N, Helbig S, Dörk T: Hereditary breast cancer: ever more pieces to the polygenic puzzle. Hered Cancer Clin Pract 2013, 11:12.
19. Varon R, Vöring L, Platter M, Cersosimo KM, Chzarowska KH, Saar K, Beckmann G, Seemanová E, Cooper PR, Nowak NJ, Stumm M, Weemaes CM, Gari RA, Wilson RK, Digweed M, Rosenthal A, Sperling K, Concan P, Reis A: Nibrin, a novel DNA double-strand break repair protein, is mutated in Nijmegen breakage syndrome. Cell 1998, 93:467–476.
20. Seemanova E, Seemanová E, Sperling K, Neitzel H, Varon R, Hadac J, Butova O, Sperling K, Concan P: Exon 20 deletion in NBS1 – a founder mutation in Polish breast cancer families. Int J Cancer 2006, 111:57–61.
21. di Maio A, Viganotti M, Pollicelli F, Ascenzi P, Tanzarella C, Antoccia A: The R215W mutation in NBS1 impairs gamma-H2AX binding and affects DNA repair: molecular bases for the severe phenotype of 657del5/R215W Nijmegen breakage syndrome patients. Biochem Biophys Res Commun 2008, 369:335–340.

22. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Pajak I, Silliman N, Dabbs S, Buckhaults P, Farell C, Meeh P, Markowitz SD, Willis J, Dabbs D, Willson JKV, Gazdar AF, Hargrave J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE: The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314:268–274.

23. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, Shen D, Boca SM, Barber T, Pajak I, Silliman N, Szabo S, Dezso Z, Ustyansky V, Nikolikaya T, Nikoliky Y, Kachin R, Wilson PA, Kaminker JS, Zhang Z, Croshaw R, Willis J, Dabbs D, Shipitsin M, Willson JKV, Sottor S, Poljak K, Park BH, Pethiyagoda CL, Krishna Pant PV: The genomic landscapes of human breast and colorectal cancers. Science 2007, 318:108–113.

24. Stephens PJ, McBride DJ, Lin ML, Varela I, Pleasance ED, Simpson JT, Stebbings LA, Leroy C, Edwards K, Mudie LJ, Greenman CD, Jia M, Latimer C, Teague J, Lau KW, Burton J, Quail MA, Swedlow H, Churcher C, Narajjan R, Seuwerds AM, Mertens J, JWM, Silver D, Langeland A, Rursnes HEG, Fockens JA, Reis-Filho JS, van ’t Veur L, Richardson AL, Barresen-Dale AL: Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 2009, 462:1005–1010.

25. Sakamoto S, Iijima K, Mochizuki D, Nakamura K, Teshigawara K, Kobayashi J, Matsuura S, Tauchi H, Suzuki H, Tashiro S, Zou L, Komatsu K: Arg215Trp mutation. IUBMB Life 2012, 64:853–861.

26. Nakamura K, Kato A, Kobayashi J, Yanagihara H, Sakamoto S, Oliveira DV, Nibrin forkhead-associated domain and

27. Cerosaletti KM, Concannon P: PARP hyperactivation and increased oxidative stress. DNA repair in Nijmegen breakage syndrome cells leads to PARP hyperactivation and increased oxidative stress. PLoS Genet 2012, 8:e1002557.

28. Cerosseltti KM, Conannon P: Nibrin forkhead-associated domain and breast cancer C-terminal domain are both required for nuclear focus formation and phosphorylation. J Biol Chem 2003, 278:21944–21951.

29. Krendl H, Demuth L, Salewsky B, Wesendorff P, Weidele K, Bürkle A, Digweed M: DNA damage in Nijmegen breakage syndrome cells leads to PARP hyperactivation and increased oxidative stress. PLoS Genet 2012, 8:e1002557.

30. Uziel T, Lerenthal Y, Moyal M, Andegeko Y, Mittelman L, Shiloh Y: Requirement of the MRN complex for ATM activation by DNA damage. EMBO J 2003, 22:5621–5626.

31. Yazdi PT, Wang Y, Zhao S, Patel N, Lee EY, Qin J: SMC1 is a downstream effector in the ATM/NBS1 branch of the human S-phase checkpoint. Cancer Res 2002, 16:571–582.

32. Kitagawa R, Bakkenist CJ, McKinnon PJ, Kastan MB: Phosphorylation of SMC1 is a critical downstream event in the ATM-NBS1-BRCA1 pathway. Genes Dev 2004, 18:1423–1438.

33. Mendez G, Cilli D, Berardinelli F, Viganotti M, Ascenzi P, Tanzarella C, Antoccia A, di Maio A: Cleavage of the BRCT tandem domains of nibrin by the 657del5 mutation affects the DNA damage response less than the Arg215Trp mutation. JUMBB Life 2012, 64:853–861.

34. Hair F, Spycher C, Jungmichel F, Pavic L, Stucki M: A divalent FHA/BRCT-binding mechanism couples the MRE11–RAD50–NBS1 complex to damaged chromatin. EMBO Rep 2010, 11:387–392.

35. Antoccia A, Sakamoto S, Matsuura S, Tauchi H, Komatsu K: NBS1 prevents chromatin-type aberrations through ATM-dependent interactions with SMC1. Radiat Res 2008, 170:345–352.

36. Bork P, Hofmann K, Bucher P, Neuwald AF, Altschul SF, Koonin EV: A superfamily of conserved domains in DNA damage responsive cell cycle checkpoint proteins. FASEB J 1997, 11:68–76.

37. Cellebaut I, Mornon JP: From BRCA1 to RAP1: a widespread BRCT module closely associated with DNA repair. FEBS Lett 1997, 400:25–30.

38. Lowndes NF, Toh GH: DNA repair: the importance of phosphorylating histone H2AX. Curr Biol 2003, 15:R99–R102.

39. Mitrou J, Kleibl B, Kleibl Z, Janatova M, Soukopova J, Ticha L, Novotny J, Pohrelich P: Germline mutations 657del5 and 643C>T (R215W) in NBN are not likely to be associated with increased risk of breast cancer in Czech women. Breast Cancer Res Treat 2012, 133:809–811.

40. di Maio A, Antoccia A: NBS1 heterozygosity and cancer risk. Curr Genomics 2008, 9:275–281.